TransMedics Group, Inc. Share Price

Equities

TMDX

US89377M1099

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 12/06/2024 BST 5-day change 1st Jan Change
141.9 USD +2.05% Intraday chart for TransMedics Group, Inc. +5.03% +79.75%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 401M 31.38B Sales 2025 * 528M 41.27B Capitalization 4.67B 365B
Net income 2024 * 29M 2.27B Net income 2025 * 42M 3.28B EV / Sales 2024 * 12.1 x
Net Debt 2024 * 185M 14.43B Net Debt 2025 * 164M 12.82B EV / Sales 2025 * 9.16 x
P/E ratio 2024 *
171 x
P/E ratio 2025 *
120 x
Employees 584
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.74%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.05%
1 week+5.03%
Current month+4.02%
1 month+9.16%
3 months+67.51%
6 months+93.85%
Current year+79.75%
More quotes
1 week
134.18
Extreme 134.181
146.12
1 month
128.29
Extreme 128.29
146.12
Current year
69.43
Extreme 69.43
146.12
1 year
36.42
Extreme 36.4201
146.12
3 years
10.00
Extreme 10
146.12
5 years
10.00
Extreme 10
146.12
10 years
10.00
Extreme 10
146.12
More quotes
Managers TitleAgeSince
Founder 55 31/07/98
Director of Finance/CFO 56 28/02/15
Chief Operating Officer 41 01/02/23
Members of the board TitleAgeSince
Chairman 79 31/12/10
Director/Board Member 66 31/12/02
Director/Board Member 68 31/12/20
More insiders
Date Price Change Volume
12/06/24 141.9 +2.05% 796,053
11/06/24 139 -3.90% 690,738
10/06/24 144.7 +5.46% 885,842
07/06/24 137.2 +3.13% 671,274
06/06/24 133 -1.53% 501,524

Delayed Quote Nasdaq, June 12, 2024 at 09:00 pm

More quotes
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
141.9 USD
Average target price
135 USD
Spread / Average Target
-4.85%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW